Clinical Trial

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-10-13; most recent amendment 2025-12-15.
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Status change: Not Yet Recruiting → Recruiting 2021-09-20
Trial Details
NCT Number NCT04594798
Lead Sponsor University of Rochester
Collaborators: Genentech, Inc.
Conditions DLBCL, Lymphoma, B-Cell
Enrollment 39 participants
Start Date 2021-09-20
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-17